The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
Open accessAbstract
BACKGROUND: As compared with a standard-dose vaccine, a high-dose, trivalent, inactivated influenza vaccine (IIV3-HD) improves antibody responses to influenza among adults 65 years of age or older. This study evaluated whether IIV3-HD also improves protection against laboratory-confirmed influenza illness. METHODS: We conducted a phase IIIb-IV, multicenter, randomized, double-blind, active-controlled trial to compare IIV3-HD (60 μg of hemagglutinin per strain) with standard-dose trivalent, inactivated influenza vaccine (IIV3-SD [15 μg of hemagglutinin per strain]) in adults 65 years of age or older. Assessments of relative efficacy, effectiveness, safety (serious adverse events), and immunogenicity (hemagglutination-inhibition [HAI] titers) were performed during the 2011-2012 (year 1) and the 2012-2013 (year 2) northern-hemisphere influenza seasons. RESULTS: A total of 31,989 participants were enrolled from 126 research centers in the United States and Canada (15,991 were randomly assigned to receive IIV3-HD, and 15,998 to receive IIV3-SD). In the intention-to-treat analysis, 228 participants in the IIV3-HD group (1.4%) and 301 participants in the IIV3-SD group (1.9%) had laboratory-confirmed influenza caused by any viral type or subtype associated with a protocol-defined influenza-like illness (relative efficacy, 24.2%; 95% confidence interval [CI], 9.7 to 36.5). At least one serious adverse event during the safety surveillance period was reported by 1323 (8.3%) of the participants in the IIV3-HD group, as compared with 1442 (9.0%) of the participants in the IIV3-SD group (relative risk, 0.92; 95% CI, 0.85 to 0.99). After vaccination, HAI titers and seroprotection rates (the percentage of participants with HAI titers ≥ 1:40) were significantly higher in the IIV3-HD group. Conclusions: Among persons 65 years of age or older, IIV3-HD induced significantly higher antibody responses and provided better protection against laboratory-confirmed influenza illness than did IIV3-SD. (Funded by Sanofi Pasteur; ClinicalTrials.gov number, NCT01427309.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“for some populations, such as older adults, a higher dose might be beneficial, as has been shown for the influenza vaccine69,70.”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [70]
Citations
Cites
Fiore, A. E., Shay, D. K., Broder, K. R., Iskander, J. K., Uyeki, T. M., Mootrey, G., Bresee, J. S., & Cox, N. S. (2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,006
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673
Influenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213
Fiore, A. E., Uyeki, T. M., Broder, K. R., Finelli, L., Euler, G. L., Singleton, J. A., Iskander, J. K., Wortley, P. M., Shay, D. K., Bresee, J., et al. (2009) · PubMed · Cited by 1,964
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100
The Efficacy of Influenza Vaccination in Elderly Individuals
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 883
Impact of Influenza Vaccination on Seasonal Mortality in the US Elderly Population
Simonsen, L., Reichert, T. A., Viboud, C. G., Blackwelder, W. C., Taylor, R. J., & Miller, M. A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.265 · Cited by 541
Falsey, A. R., Treanor, J. J., Tornieporth, N., Capellan, J., & Gorse, G. J. (2009) · The Journal of Infectious Diseases · doi:10.1086/599790 · Cited by 388
Self-citationInfluenza Activity — United States, 2015–16 Season and Composition of the 2016–17 Influenza Vaccine
Davlin, S. L., Blanton, L., Kniss, K. L., Mustaquim, D., Smith, S., Kramer, N. A., Cohen, J., Cummings, C. N., Garg, S., Flannery, B. L., et al. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6522a3 · Cited by 328
Research works printed but not linked: 7
- Fiore AE, 2010, MMWR Recomm Rep, 59, 1
- Praditsuwan R, 2005, J Med Assoc Thai, 88, 256
- 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I · DOI · Paper page
- 2012, MMWR Morb Mortal Wkly Rep, 61, 414
- 2013, MMWR Morb Mortal Wkly Rep, 62, 997
- 2013, MMWR Morb Mortal Wkly Rep, 62, 473
- 2013, Wkly Epidemiol Rec, 88, 101
Cited by
Sorted by citations
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Walter, E. B., Fry, A. M., & Jernigan, D. B. (2018) · MMWR Recommendations and Reports · doi:10.15585/mmwr.rr6703a1 · Cited by 1,640
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
Krammer, F., Smith, G. J. D., Fouchier, R. A. M., Peiris, M. J. S., Kedzierska, K., Doherty, P. C., Palese, P., Shaw, M. L., Treanor, J. J., Webster, R. G., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0002-y · Cited by 1,591
Self-citationAlternatives to antibiotics—a pipeline portfolio review
Czaplewski, L. G., Bax, R. P., Clokie, M. R. J., Dawson, M., Fairhead, H., Fischetti, V. A., Foster, S. J., Gilmore, B., Hancock, R. E. W., Harper, D. J., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00466-1 · Cited by 880
Metadata
- Authors
- DiazGranados, C. A., Dunning, A. J., Kimmel, M., Kirby, D., Treanor, J., Collins, A., Pollak, R., Christoff, J., Earl, J., Landolfi, V., Martin, E., Gurunathan, S., Nathan, R., Greenberg, D. P., Tornieporth, N. G., Decker, M. D., & Talbot, H. K.
- Affiliations
- University of Pittsburgh (US)
- University of Rochester (US)
- PMG Research (US)
- Martin Diagnostic Clinic (US)
- Vanderbilt University (US)
- Vanderbilt University Medical Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-08-14
- Volume
- 371
- Issue
- 7
- Pages
- 635-645
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168805652
- Cited by
- 876
- References
- 29
- Citations by year
- 2026: 76 · 2025: 89 · 2024: 60 · 2023: 78 · 2022: 68 · 2021: 95 · 2020: 80 · 2019: 78 · 2018: 68 · 2017: 65 · 2016: 65 · 2015: 42 · 2014: 10
- FWCI
- 45.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- high-dose influenza vaccine, trivalent inactivated influenza vaccine, older adults, vaccine efficacy, laboratory-confirmed influenza, hemagglutination inhibition titers, immunogenicity, seroprotection, serious adverse events, influenza vaccination, 2011-2012 influenza season, 2012-2013 influenza season, antibody response
- MeSH terms
- Aged, Antibodies, Viral, Chronic Disease, Double-Blind Method, Female, Humans, Influenza, Human, Influenza Vaccines, Male, Orthomyxoviridae, Vaccines, Inactivated, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
